Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study
Journal for ImmunoTherapy of Cancer · 2025-02 · 13 (2) · e010065
DOI: 10.1136/jitc-2024-010065 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 06.02.2025. Verfasst von Michiel M Smeenk und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but come with high costs. Alternative ICI dosing strategies could reduce costs without losing efficacy. However, clinical efficacy data are lacking.
Methods
In this retrospective cohort trial, consecutive patients with advanced non-small cell lung cancer (NSCLC) who received ≥1 cycle pembrolizumab±chemotherapy at two tertiary institutions were included. Hybrid dosed patients received either 100, 150 or 200 mg pembrolizumab every 3 weeks or double every 6 weeks depending on their weight: 90 kg, respectively. Standard-of-care flat dosed patients received 200 mg every 3 weeks or 400 mg every 6 weeks. Overall survival (OS) and progression-free survival (PFS) were assessed by Kaplan-Meier estimation, compared by log-rank test and HRs were calculated with the Cox proportional hazards model in both unweighted and inverse probability of treatment weighted (IPTW) cohorts. Non-inferiority margin was set at an HR of 1.15.
Results
In total, 375 patients and 391 patients were included and median follow-up was 43.1 and 61.0 months in the hybrid and flat dose cohort, respectively. OS was non-inferior in the hybrid dose cohort compared with the flat dose cohort: median 17.7 months (95% CI 14.9 to 20.9) vs 11.8 months (95% CI 9.3 to 13.8, HR 0.76, 95% CI 0.65 to 0.90, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Pharmacy, Haga Teaching Hospital, The Hague, The Netherlands.
Zitieren
APA
Smeenk, M. M., van der Noort, V., Hendrikx, J. M. A., Abedian Kalkhoran, H., Smit, E. F., & Theelen, W. S. M. E. (2025). Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study. Journal for ImmunoTherapy of Cancer, 13(2), e010065. https://doi.org/10.1136/jitc-2024-010065
Vancouver
Smeenk MM, van der Noort V, Hendrikx JMA, Abedian Kalkhoran H, Smit EF, Theelen WSME. Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study. Journal for ImmunoTherapy of Cancer. 2025;13(2):e010065. doi:10.1136/jitc-2024-010065
BibTeX
@article{Smeenk2025,
author = {Smeenk, Michiel M and van der Noort, Vincent and Hendrikx, Jeroen M A and Abedian Kalkhoran, Hanieh and Smit, Egbert F and Theelen, Willemijn S M E},
title = {Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {2},
pages = {e010065},
doi = {10.1136/jitc-2024-010065}
}
EUVIMED